About Medtronic plc
Medtronic plc is a global leader in healthcare technology. Founded in 1949 and headquartered in Galway, Ireland, the company develops medical devices, technologies, and therapies that alleviate pain, restore health, and extend life across more than 70 chronic health conditions.
Core Business Portfolios & Focus Areas
| Portfolio Segment | Focus Areas & Clinical Applications |
|---|---|
| Cardiovascular | Pacemakers, defibrillators, cardiac ablation systems, transcatheter aortic valves, coronary/peripheral vascular devices, and structural heart care. |
| Neuroscience | Neuromodulation devices, cranial and spinal technologies, neurovascular therapies, surgical navigation systems, and neuro-spine robotics. |
| Medical-Surgical | Surgical instrumentation, advanced stapling, soft-tissue robotic surgical platforms, and acute care/patient monitoring systems. |
| Diabetes | Continuous glucose monitoring (CGM) systems, automated insulin delivery systems, and smart insulin pens. |
AI, Robotics & Digital Technology Ecosystem
- Hugo Surgical Robot System: Modular, multi-quadrant robotic-assisted surgery system integrated with advanced instruments like the LigaSure RAS Maryland tool.
- AI & Intelligent Imaging: GI Quantix and AI-powered diagnostic platforms embedded into endoscopic devices to improve real-time decision-making and polyp detection.
- Digital Surgery & Analytics: Touch Surgery cloud-based digital platform enabling surgical video capture, AI analysis, and procedural workflow management.
- Automated Care Delivery: Closed-loop algorithms pairing continuous glucose monitors with smart insulin pumps to automate personalized care.
Impact Metrics & Financial Commitments (FY2026)
- Global Patient Impact: Served over 82 million patients worldwide in FY2026.
- Research & Development Investment: Direct commitment of $2.9 Billion in R&D during FY2026 to fuel next-generation healthcare innovations.
- Clinical Validation: Active execution of 180+ clinical trials in FY2026 to evaluate procedural safety, device performance, and therapeutic outcomes.
- Commercial Performance: Generated $36.36 Billion in total worldwide revenue in FY2026, delivering the strongest annual growth trajectory in a decade.
Clinical & Market Applications
- Rhythm Management & Electrophysiology: Pulsed-field ablation (PFA) and leadless pacemakers for cardiac arrhythmias and heart failure.
- Minimally Invasive Surgery: Robotic-assisted interventions, advanced vessel sealing, and automated tissue stapling.
- Spine & Neurological Care: Robot-guided spine fusion, deep brain stimulation (DBS) for movement disorders, and stroke intervention.
- Chronic Disease Management: Continuous glucose tracking and automated insulin delivery for type 1 and type 2 diabetes.